Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal Q1 revenue rises 5% to $695 million; GAAP profit $12 million; guidance affirmed

Positive Impact 3 of 5 earnings Written later

Amneal Pharmaceuticals reported first-quarter 2025 net revenue of $695 million, up 5% from $659 million a year earlier, and net income attributable to the company of $12 million, compared with a net loss of $92 million in the first quarter of 2024. The company reaffirmed its full-year 2025 guidance, including net revenue of $3.0 billion to $3.1 billion and adjusted diluted EPS of $0.65 to $0.70, so shareholders see improved results with no change to the outlook.

Key points

  • Net revenue $695 million, up 5% from $659 million; Affordable Medicines up 6%, Specialty up 3%, AvKARE up 6%
  • GAAP diluted EPS $0.04 versus a loss of $0.30; adjusted diluted EPS $0.21, up 50% from $0.14
  • Adjusted EBITDA $170 million, up 12% from the prior-year quarter
  • Full-year 2025 guidance affirmed: adjusted EBITDA $650 million to $675 million; conference call at 8:30 am Eastern on May 2, 2025

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECMay 2, 2025, 6:18 AM ET
Accession number0001723128-25-000018

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 02, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.